Form 8-K FDA Augment


 


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): August 8, 2013



WRIGHT MEDICAL GROUP, INC.
(Exact name of registrant as specified in charter)



Delaware
001-35823
13-4088127
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)



5677 Airline Road,
Arlington, Tennessee
38002
(Address of Principal Executive Offices)
(Zip Code)



Registrant's telephone number, including area code: (901) 867-9971


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))    
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01 Other Events.
On August 8, 2013 Wright Medical Group, Inc. issued a press release announcing the receipt of a not approvable letter from the FDA for Augment Bone Graft. The press release is attached as exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.
(d)     Exhibits

99.1
Press release dated August 8, 2013





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 8, 2013

 
WRIGHT MEDICAL GROUP, INC.
 
By: /s/ Lance A. Berry
 
Lance A. Berry
 
Senior Vice President and Chief Financial Officer






EXHIBIT INDEX

99.1
Press release dated August 8, 2013